Michael Schmidt

Rain Oncology's Phase 3 Data Casts Doubt On Other Trials: Analyst Reevaluate Their Views

Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation

A Bull And Bear Review Positive Results For Puma Biotech's Late-Stage Breast Cancer Drug Trial

Arvinas TPD Therapies Have Great Potential, Guggenheim Says In Bullish Initiation

A Bull And Bear Review Positive Results For Puma Biotech's Late-Stage Breast Cancer Drug Trial

Leerink: Bluebird Bio's Catalysts Are Priced In

The Street Has Finally Recognized The Exelixis Clinical Program Potential

Leerink: Bluebird Bio's Catalysts Are Priced In

The Street Has Finally Recognized The Exelixis Clinical Program Potential

Mirati Therapeutics Sitravatinib Data, Explained

Array Biopharma Sees Positive Study Results From COLUMBUS Phase 2, But Commercialization May Prove Daunting

Michael Schmidt Recent News

Agios Pharma Shares Crushed Under Weight Of Clinical Setback

Leerink Expects Ariad Pharmaceuticals To Outperform

Leerink Highlights Biotechs Poised To Benefit From ASH Conference

UPDATE: Leerink Partners Initiates Coverage On Five Prime Therapeutics On Multiple Value Drivers

Leerink Initiates Coverage On Five Prime Therapeutics

UPDATE: Leerink Says Tekmira Is 'Uniquely Positioned'